Evidence map›Paper›PMID 37834952›Full record

ArticleJournal of clinical medicine2023

The Relationship between the Burden of Acromegaly, Associated Comorbidities, Complications and Disease Status.

Michał Elbaum, Marcin Kałużny, Aleksandra Jawiarczyk-Przybyłowska, Beata Wojtczak, Grzegorz Zieliński, Marek Bolanowski

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. The acromegaly patient experience: burden of treatment and quality of life.The Journal of clinical endocrinology and metabolism · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michał ElbaumDepartment of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wybrzeże L. Pasteura 4, 50-367 Wroclaw, Poland.
Marcin KałużnyDepartment of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wybrzeże L. Pasteura 4, 50-367 Wroclaw, Poland.
Aleksandra Jawiarczyk-PrzybyłowskaDepartment of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wybrzeże L. Pasteura 4, 50-367 Wroclaw, Poland.
Beata WojtczakDepartment of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Borowska Str. 213, 50-556 Wroclaw, Poland.
Grzegorz ZielińskiDepartment of Neurosurgery, Military Institute of Medicine-National Research Institute, 128 Szaserów Str., 04-141 Warsaw, Poland.
Marek BolanowskiDepartment of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wybrzeże L. Pasteura 4, 50-367 Wroclaw, Poland.ORCID 0000-0002-2360-6596
Wroclaw Medical University · PLWojskowy Instytut Medycyny Lotniczej · PL

Funding

IPSEN POLAND A-PL-52030-372
6 · The paper itself

Abstract

Uncontrolled acromegaly causes increased morbidity and mortality. The analysis of acromegaly comorbidities and complications is important when establishing a standard of care for the entire population of acromegaly patients. The aim of this study was to determine the frequency of comorbidities and complications of acromegaly and their dependence on the activity of the disease. A retrospective analysis of medical records from 124 patients with acromegaly was carried out, including 39 who were cured, 73 treated with somatostatin analogs and 12 newly diagnosed patients. The incidence of comorbidities and complications was very high, and those most frequently observed were arterial hypertension, multinodular goiter, lipid disorders, hypopituitarism and degenerative changes. At least one complication of acromegaly was observed in 92% of patients undergoing successful neurosurgery and in all pharmacologically treated patients. By contrast, two or more complications were observed in 77% of cured patients and in pharmacologically controlled and uncontrolled patients, 82% and 91%, respectively. Conclusions: Acromegaly is associated with a high prevalence of complications. Active acromegaly is associated with a higher incidence of complications than in treated groups. Untreated patients have more complications than treated patients. Successfully cured patients have significantly fewer complications than pharmacologically controlled patients and patients with active acromegaly.

Indexed as

acromegalycomorbiditiescomplicationstherapy

Identifiers

PMID37834952
PMCPMC10573270
OpenAlexW4387265228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.